Virtual Library
Start Your Search
J.M. Cabrera Romero
Author of
-
+
P3.03 - Poster Session with Presenters Present (ID 473)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.03-054 - Review and Descriptive Analysis of 140 Patients Diagnosed with Malignant Mesothelioma at Consorci Sanitari Parc Tauli (ID 5855)
14:30 - 14:30 | Author(s): J.M. Cabrera Romero
- Abstract
Background:
Mesothelioma is a deadly neoplasia related to asbestos, a mineral extensively used in Spain in the 1970-80s until its ban in 2001. The incidence of mesothelioma in the region of Vallès is 1.73 cases / 100,000 inhabitants / year, five times higher than the national average, due to the industrial activity of the area. This rise is likely to increase in the forthcoming years .
Methods:
We describe the epidemiological, diagnostic, pathological and therapeutic characteristics and the overall survival of 140 patients with mesothelioma diagnosed between April 1995 and December 2015 at a single centre.
Results:
The median age was 70 years (44-89), 72.9% were males and 60% had been exposed to asbestos. A total of 55.7% were ECOG 0-1. The origin was pleural in 85% and peritoneal in 12.9%. Histology was: epithelioid in 45%, biphasic in 13.6%, sarcomatoid in 12.9% and unknown in 28.5%. All patients were clinically staged, 31.8% were EIII and 31.8% EIV. Pleurodesis was performed in 43.6%. Fifty percent of patients received palliative chemotherapy (66.2% a combination of platinum plus pemetrexed, 12.7% platinum plus gemcitabine). They received a median of 5 cycles (1-9). The response rate was 43.7%, with 26.8% stabilizations. Reasons for treatment discontinuation were: progression in 36.6% and toxicity in 12.7%. At the time of progression ECOG was 0-1 in 57.7%. Second-line treatment was administered in 46.5%. The median overall survival was 7.4 months (95% CI 4.98-9.91), with significant differences depending on the number of lines of treatment received: 0 vs. 1 vs. ≥2 (3, 8.5, 21.2 months p <0.001). Univariate analysis identified histology (p = 0.033), localization (p <0.001), ECOG (p <0.001), leukocytosis (p = 0.046) and LDH (p <0.001), as potential prognostic factors.
Conclusion:
The results are consistent with the published literature. We found significant differences in survival according to histology, location, ECOG and other prognostic factors previously explored.
